Boston, MA 10/15/2013 (wallstreetpr) – Boston Scientific Corporation (NYSE:BSX) has been trading in green ahead of its third quarter earnings to be declared on October 24’2013. It has been a view that the company is engaged in a revival attempt which could be reflected in its second quarter results as well.
The company which is a medical device marketer manufacturerposted the revenues of $1.81 billion in its second quarter results, which was above the market consensus estimate of $1.78 billion. In percentage terms, this was a 2 percent growth against the previous year’s revenues in the same quarter. As per the earnings reported in its second quarter, the company’s earning per share was $0.18 which was reasonably well above the market estimate of $0.16 earnings per share. These earnings were strongly above the $0.17 earnings per share reported in the same quarter in the previous year.
During the Monday’s trade, the company’s share surged by 2.86% and settled at $12.21 after touching the high of $12.34. The stock has 52 week high price range of $12.34 while the 52 week low price range is $5.04. During after hours, the stock price edged up by $0.08 to $12.29.This is in contradiction to what the company’s stocks have been performing lately as they were closing in red but with expectations of medicaldevice market to do better could turn the profitability back on tracks. It would be an important to note that the company has lately reshuffled its growth objectives in the near term and the sales could improve if the Cardiac Rhythm Management and Cardiology markets stabilize in the next three years.
Until the Boston’s lined up strategies are not visible in its prices, the analysts continue to rate it as ‘hold’ with a price target of $9.69, below the current market price of $12.21.
